Distinct Clinicogenomic Contexts of BRAF-Altered Gliomas and Glioneuronal Tumors: A Nationwide Real-World Study.
4 affiliations
- 1Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Japan.
- 2Department of Genomic Medicine, School of Medicine, Fujita Health University, Toyoake, Japan.
- 3Department of Diagnostic Pathology, Fujita Health University School of Medicine, Toyoake, Japan.
- 4Department of Neurosurgery, Fujita Health University School of Medicine, Toyoake, Japan.
Abstract
BRAF alterations occur across diverse gliomas and glioneuronal tumors, but their alteration-specific clinicogenomic contexts in real-world cancer genomic profiling cohorts remain incompletely characterized. We analyzed BRAF-altered brain tumors registered in the Japanese Center for Cancer Genomics and Advanced Therapeutics database from June 2019 to March 2026. Operational diagnostic harmonization was performed using available clinicopathological and genomic information. Grade-stratified analyses focused on BRAF p.V600E-positive gliomas and glioneuronal tumors. Among 413 BRAF-altered brain tumors, 344 were classified as gliomas and glioneuronal tumors after harmonization. Within this cohort, the major alteration contexts included BRAF p.V600E-positive tumors (n = 166), KIAA1549::BRAF fusion-positive tumors (n = 60), amplification-only tumors (n = 15), and tumors with other BRAF alterations (n = 109), with overlap in a subset. KIAA1549::BRAF fusion-positive tumors were mainly associated with low-grade glioma contexts, particularly pilocytic astrocytoma. Amplification-only tumors showed marked enrichment of MET alterations, all representing MET amplification, together with frequent EGFR and TP53 co-alterations, supporting a receptor tyrosine kinase-amplified, copy-number-rich context. Among 118 grade-evaluable BRAF p.V600E-positive gliomas and glioneuronal tumors, CDKN2A/B homozygous deletion and TP53/ATRX alterations were enriched in higher-grade groups, and high-grade tumors showed increased tumor mutational burden, although hypermutator phenotypes were rare. BRAF alteration classes define distinct clinicogenomic contexts in gliomas and glioneuronal tumors. These findings highlight both the opportunities and methodological challenges of nationwide real-world cancer genomic profiling datasets in central nervous system tumor research.
Related
- ALTERED AND DISTINCT IODOTHYRONINE DEOIDINASE M-RNA EXPRESSION PROFILES IN SURGICAL SPECIMENS OF MULTINODULAR GOITRE AND DIFFERENTIATED THYROID CARCINOMA
- Diffuse Leptomeningeal Glioneuronal Tumor With Initial Diagnosis of Pilocytic Astrocytoma With Anaplasia: A Case Study
- Adult-onset familial hemophagocytic lymphohistiocytosis has distinct genetic architecture and outcomes: a nationwide multicenter cohort study in China.
- Clinicogenomic characterization and targeted therapy efficacy in Chinese patients with NTRK fusion-positive thyroid cancer: a preliminary retrospective cohort study.
- Choroid plexus volume variation in patients with gliomas, glioneuronal and neuronal tumors: Associations with tumor characteristics
BibTeX
@article{yamada2026distinct,
title = {{Distinct Clinicogenomic Contexts of BRAF-Altered Gliomas and Glioneuronal Tumors: A Nationwide Real-World Study.}},
author = {Seiji Yamada and Tetsuya Takimoto and Sayaka Ueno and Sachiko Minamiguchi and Shigeo Ohba and Yuichi Hirose and Hideyuki Saya and Tamotsu Sudo},
journal = {Cancer science},
year = {2026},
month = oct,
doi = {10.1111/cas.70568},
url = {https://europepmc.org/article/MED/42894377},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Distinct Clinicogenomic Contexts of BRAF-Altered Gliomas and Glioneuronal Tumors: A Nationwide Real-World Study.
AU - Seiji Yamada
AU - Tetsuya Takimoto
AU - Sayaka Ueno
AU - Sachiko Minamiguchi
AU - Shigeo Ohba
AU - Yuichi Hirose
AU - Hideyuki Saya
AU - Tamotsu Sudo
PY - 2026
DA - 2026/10/18
JO - Cancer science
DO - 10.1111/cas.70568
UR - https://europepmc.org/article/MED/42894377
AB - BRAF alterations occur across diverse gliomas and glioneuronal tumors, but their alteration-specific clinicogenomic contexts in real-world cancer genomic profiling cohorts remain incompletely characterized. We analyzed BRAF-altered brain tumors registered in the Japanese Center for Cancer Genomics and Advanced Therapeutics database from June 2019 to March 2026. Operational diagnostic harmonization was performed using available clinicopathological and genomic information. Grade-stratified analyses focused on BRAF p.V600E-positive gliomas and glioneuronal tumors. Among 413 BRAF-altered brain tumors, 344 were classified as gliomas and glioneuronal tumors after harmonization. Within this cohort, the major alteration contexts included BRAF p.V600E-positive tumors (n = 166), KIAA1549::BRAF fusion-positive tumors (n = 60), amplification-only tumors (n = 15), and tumors with other BRAF alterations (n = 109), with overlap in a subset. KIAA1549::BRAF fusion-positive tumors were mainly associated with low-grade glioma contexts, particularly pilocytic astrocytoma. Amplification-only tumors showed marked enrichment of MET alterations, all representing MET amplification, together with frequent EGFR and TP53 co-alterations, supporting a receptor tyrosine kinase-amplified, copy-number-rich context. Among 118 grade-evaluable BRAF p.V600E-positive gliomas and glioneuronal tumors, CDKN2A/B homozygous deletion and TP53/ATRX alterations were enriched in higher-grade groups, and high-grade tumors showed increased tumor mutational burden, although hypermutator phenotypes were rare. BRAF alteration classes define distinct clinicogenomic contexts in gliomas and glioneuronal tumors. These findings highlight both the opportunities and methodological challenges of nationwide real-world cancer genomic profiling datasets in central nervous system tumor research.
SN - 1347-9032
SN - 1349-7006
ER -